Shares of Evoke Pharma Inc (NASDAQ:EVOK) saw strong trading volume on Wednesday . 4,415 shares were traded during trading, a decline of 98% from the previous session’s volume of 187,003 shares.The stock last traded at $0.95 and had previously closed at $0.99.

A number of analysts have weighed in on the stock. Zacks Investment Research raised shares of Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research note on Tuesday, August 13th. HC Wainwright reaffirmed a “hold” rating on shares of Evoke Pharma in a research note on Friday, August 9th. Finally, ValuEngine upgraded shares of Evoke Pharma from a “sell” rating to a “hold” rating in a report on Thursday, August 1st.

The company has a market cap of $23.03 million, a price-to-earnings ratio of -2.07 and a beta of 1.63. The business’s fifty day moving average price is $0.93 and its 200 day moving average price is $0.92.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. Research analysts forecast that Evoke Pharma Inc will post -0.35 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Evoke Pharma stock. Marshall Wace LLP bought a new stake in Evoke Pharma Inc (NASDAQ:EVOK) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 92,406 shares of the specialty pharmaceutical company’s stock, valued at approximately $139,000. Marshall Wace LLP owned 0.40% of Evoke Pharma as of its most recent SEC filing. 5.50% of the stock is owned by institutional investors.

About Evoke Pharma (NASDAQ:EVOK)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Read More: How to Calculate Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with's FREE daily email newsletter.